Skip to Content


Generic Name: Indomethacin
Class: Other Nonsteroidal Anti-inflammatory Agents
CAS Number: 53-86-1

Medically reviewed by Last updated on Nov 11, 2019.


Special Alerts:

For information on the use of this drug in patients with coronavirus disease 2019 (COVID-19), see the document “Assessment of the Evidence for COVID-19-Related Treatments” on ASHP's COVID-19 Resource Center. To view this document, please click here: [Web]


    Cardiovascular Risk
  • Increased risk of serious (sometimes fatal) cardiovascular thrombotic events (e.g., MI, stroke).420 500 502 508 Risk may occur early in treatment and may increase with duration of use.500 502 505 506 508 (See Cardiovascular Thrombotic Effects under Cautions.)

  • Contraindicated in the setting of CABG surgery.508

    GI Risk
  • Increased risk of serious (sometimes fatal) GI events (e.g., bleeding, ulceration, perforation of the stomach or intestine).420 Serious GI events can occur at any time and may not be preceded by warning signs and symptoms.420 Geriatric individuals are at greater risk for serious GI events.420 (See GI Effects under Cautions.)


Prototypical NSAIA; indoleacetic acetic acid derivative.301 341 420

Uses for Indocin

When used for inflammatory diseases, consider potential benefits and risks of indomethacin therapy as well as alternative therapies before initiating therapy with the drug.420 Use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.420

Inflammatory Diseases

Symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.341 420

Symptomatic relief of acute gout and acute painful shoulder (i.e., bursitis and/or tendinitis).341 420

Management of juvenile rheumatoid arthritis in children ≥2 years of age.420

Patent Ductus Arteriosus (PDA)

Treatment of PDA in premature neonates.301 302 303 304 305 306 308 309 310 311 312 313 314 316 318 319 320 322 323 324 325 326 Used to promote closure of a hemodynamically significant PDA (i.e., left-to-right shunt large enough to compromise cardiorespiratory status) in premature neonates weighing 500–1750 g when 36–48 hours of usual medical management (e.g., fluid restriction, diuretics, cardiac glycosides, respiratory support) is ineffective.301 306 307 313


Reduction of pain, fever, and inflammation of pericarditis;a however, in the treatment of post-MI pericarditis, NSAIAs are potentially harmful and aspirin is the treatment of choice.491 (See Cardiovascular Thrombotic Effects under Cautions.)

Indocin Dosage and Administration


  • For inflammatory diseases, consider potential benefits and risks of indomethacin therapy as well as alternative therapies before initiating therapy with the drug.420


Administer orally or rectally (for inflammatory diseases or pericarditis)341 420 or by IV infusion (for PDA).301

Oral Administration

In patients who have persistent night pain and/or morning stiffness, a large portion (maximum 100 mg) of the total daily dose may be given at bedtime.341 420

Conventional Capsules and Oral Suspension

Administer conventional capsules and oral suspension in 2–4 divided doses daily.420

Extended-release Capsules

Administer extended-release capsules once or twice daily.341

Extended-release capsules can be used as an alternative to conventional capsules: 75 mg once daily (extended-release) as an alternative to 25 mg 3 times daily (conventional); 75 mg twice daily (extended-release) as an alternative to 50 mg 3 times daily (conventional).341

Swallow extended-release capsules intact.341

Extended-release capsules are not recommended for treatment of acute gouty arthritis.341

Rectal Administration

Administer in 2–4 divided doses daily.420

Retain suppositories in rectum for ≥1 hour to ensure complete absorption.420

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion.301

Avoid extravasation (irritating to extravascular tissues).301


Reconstitute vial containing 1 mg of indomethacin with 1 or 2 mL of preservative-free 0.9% sodium chloride injection or sterile water for injection to provide a solution containing 1 mg/mL or 0.5 mg/mL, respectively.301 Further dilution is not recommended.301

Use of bacteriostatic water for injection containing benzyl alcohol is not recommended because of potential risk of benzyl alcohol exposure if administered to a neonate.301

Prepare solutions immediately before use; discard any unused solution.301

Rate of Administration

Optimum rate not established; may administer dose over 20–30 minutes.301


Available as indomethacin and indomethacin sodium; dosage expressed in terms of indomethacin.301 341 420

To minimize the potential risk of adverse cardiovascular and/or GI events, use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.420 Adjust dosage based on individual requirements and response; attempt to titrate to the lowest effective dosage.420

Pediatric Patients

Inflammatory Diseases
Juvenile Rheumatoid Arthritis

Children ≥2 years of age: Initially, 1–2 mg/kg daily in divided doses.341 420 Increase dosage until a satisfactory response is achieved, up to maximum dosage of 3 mg/kg daily or 150–200 mg daily (whichever is less) in divided doses; limited data support the use of a maximum dosage of 4 mg/kg daily or 150–200 mg daily (whichever is less) in divided doses.341 420 As symptoms subside, reduce dosage to the lowest effective level or discontinue the drug.341 420


Each course of therapy consists of up to 3 doses administered at 12- to 24-hour intervals.301

Base dosage on neonate’s age at the time therapy is initiated.301

Dosage for the Management of PDA in Neonates

Age at First Dose

First Dose

Second Dose

Third Dose

<48 hours

0.2 mg/kg

0.1 mg/kg

0.1 mg/kg

2–7 days

0.2 mg/kg

0.2 mg/kg

0.2 mg/kg

>7 days

0.2 mg/kg

0.25 mg/kg

0.25 mg/kg

If anuria or oliguria (urine output <0.6 mL/kg per hour) is present at the time of a second or third dose, withhold the dose until laboratory determinations indicate that renal function has returned to normal.301

If ductus arteriosus closes or is substantially constricted 48 hours or longer after completion of the first course, no further doses are necessary.301

If ductus reopens, a second course of 1–3 doses may be administered.301 Surgical ligation may be necessary if ductus is unresponsive to 2 courses of therapy.301


50–100 mg daily in 2–4 divided doses.a


Inflammatory Diseases
Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis

Conventional capsules or oral suspension: Initially, 25 mg 2 or 3 times daily.420 If needed, increase dosage by 25 or 50 mg daily at weekly intervals until a satisfactory response is obtained up to a maximum dosage of 150–200 mg daily.420

Extended-release capsules: Initially, 75 mg once daily.341 May increase dosage to 75 mg twice daily.341


25 mg 2 or 3 times daily. If needed, increase dosage by 25 or 50 mg daily at weekly intervals until a satisfactory response is obtained up to a maximum dosage of 150–200 mg daily.420


Conventional capsules: 50 mg 3 times daily until pain is tolerable; then reduce dosage rapidly and discontinue.420

Painful Shoulder

Conventional capsules or oral suspension: 75–150 mg daily in 3 or 4 divided doses.420 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.420

Extended-release capsules: 75 mg once or twice daily.341 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.341


75–150 mg daily in 3 or 4 divided doses.420 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.420

Prescribing Limits

Pediatric Patients

Juvenile Rheumatoid Arthritis

Maximum 4 mg/kg or 150–200 mg daily, whichever is less.420


Inflammatory Diseases
Rheumatoid Arthritis, Osteoarthritis, or Ankylosing Spondylitis

Maximum 200 mg daily.420


Maximum 200 mg daily.420

Special Populations

Geriatric Patients

Careful dosage selection recommended due to possible age-related decreases in renal function.341 420

Cautions for Indocin


  • Known hypersensitivity to indomethacin or any ingredient in the formulation.341 420

  • History of asthma, urticaria, or other sensitivity reaction precipitated by aspirin or other NSAIAs.341 420

  • In the setting of CABG surgery.508

  • When administered rectally, history of proctitis or recent rectal bleeding.420

  • When used for PDA, known or suspected untreated infection; bleeding, especially active intracranial hemorrhage or GI bleeding; thrombocytopenia; coagulation defects; known or suspected necrotizing enterocolitis; substantial renal impairment; congenital heart disease if patency of the ductus arteriosus is necessary for pulmonary or systemic blood flow (e.g., pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta).301



Cardiovascular Thrombotic Effects

NSAIAs (selective COX-2 inhibitors, prototypical NSAIAs) increase the risk of serious adverse cardiovascular thrombotic events (e.g., MI, stroke) in patients with or without cardiovascular disease or risk factors for cardiovascular disease.500 502 508

Findings of FDA review of observational studies, meta-analysis of randomized controlled trials, and other published information500 501 502 indicate that NSAIAs may increase the risk of such events by 10–50% or more, depending on the drugs and dosages studied.500

Relative increase in risk appears to be similar in patients with or without known underlying cardiovascular disease or risk factors for cardiovascular disease, but the absolute incidence of serious NSAIA-associated cardiovascular thrombotic events is higher in those with cardiovascular disease or risk factors for cardiovascular disease because of their elevated baseline risk.500 502 506 508

Increased risk may occur early (within the first weeks) following initiation of therapy and may increase with higher dosages and longer durations of use.500 502 505 506 508

In controlled studies, increased risk of MI and stroke observed in patients receiving a selective COX-2 inhibitor for analgesia in first 10–14 days following CABG surgery.508

In patients receiving NSAIAs following MI, increased risk of reinfarction and death observed beginning in the first week of treatment.505 508

Increased 1-year mortality rate observed in patients receiving NSAIAs following MI;500 508 511 absolute mortality rate declined somewhat after the first post-MI year, but the increased relative risk of death persisted over at least the next 4 years.508 511

Some systematic reviews of controlled observational studies and meta-analyses of randomized studies suggest naproxen may be associated with lower risk of cardiovascular thrombotic events compared with other NSAIAs.487 488 489 490 500 501 502 503 506 FDA states that limitations of these studies and indirect comparisons preclude definitive conclusions regarding relative risks of NSAIAs.500

Use NSAIAs with caution and careful monitoring (e.g., monitor for development of cardiovascular events throughout therapy, even in those without prior cardiovascular symptoms) and at the lowest effective dosage for the shortest duration necessary.420 500 508

Some clinicians suggest that it may be prudent to avoid NSAIA use, whenever possible, in patients with cardiovascular disease.505 511 512 516 Avoid use in patients with recent MI unless benefits of therapy are expected to outweigh risk of recurrent cardiovascular thrombotic events; if used, monitor for cardiac ischemia.508 Contraindicated in the setting of CABG surgery.508

No consistent evidence that concomitant use of low-dose aspirin mitigates the increased risk of serious adverse cardiovascular events associated with NSAIAs.420 502 508 (See Specific Drugs under Interactions.)

GI Effects

Serious GI toxicity (e.g., bleeding, ulceration, perforation) can occur with or without warning symptoms; increased risk in those with a history of GI bleeding or ulceration, geriatric patients, smokers, those with alcohol dependence, and those in poor general health.420

Incidence of major GI bleeding reported in neonates receiving IV indomethacin in clinical studies similar to that in neonates receiving placebo; minor GI bleeding occurred more frequently in indomethacin-treated neonates.301

When used for inflammatory diseases in patients at high risk for complications from NSAIA-induced GI ulceration (e.g., bleeding, perforation), consider concomitant use of misoprostol;457 464 alternatively, consider concomitant use of a proton-pump inhibitor (e.g., omeprazole)457 464 or use of an NSAIA that is a selective inhibitor of COX-2 (e.g., celecoxib).464


Hypertension and worsening of preexisting hypertension reported; either event may contribute to the increased incidence of cardiovascular events.420 Use with caution in patients with hypertension; monitor BP.420

Impaired response to ACE inhibitors, angiotensin II receptor antagonists, β-blockers, and certain diuretics may occur.420 508 (See Specific Drugs under Interactions.)

Heart Failure and Edema

Fluid retention and edema reported.341 420 508

NSAIAs (selective COX-2 inhibitors, prototypical NSAIAs) may increase morbidity and mortality in patients with heart failure.500 501 504 507 508

NSAIAs may diminish cardiovascular effects of diuretics, ACE inhibitors, or angiotensin II receptor antagonists used to treat heart failure or edema.508 (See Specific Drugs under Interactions.)

Manufacturer recommends avoiding use in patients with severe heart failure unless benefits of therapy are expected to outweigh risk of worsening heart failure; if used, monitor for worsening heart failure.508

Some experts recommend avoiding use, whenever possible, in patients with reduced left ventricular ejection fraction and current or prior symptoms of heart failure.507

Renal Effects

Direct renal injury, including renal papillary necrosis, reported in patients receiving long-term NSAIA therapy.341 420

Potential for overt renal decompensation.341 420 Increased risk of renal toxicity in adults with renal or hepatic impairment or heart failure, in patients with volume depletion, in geriatric patients, and in those receiving a diuretic, ACE inhibitor, or angiotensin II receptor antagonist.420 486 (See Renal Impairment under Cautions.)

May precipitate renal insufficiency in neonates; increased risk in those with extracellular volume depletion, CHF, sepsis, or hepatic dysfunction or those receiving concomitant therapy with a nephrotoxic drug.301 If a substantial reduction in urine output occurs, withhold additional doses until output returns to normal.301 (See PDA under Dosage and Administration.)

Hyponatremia reported in neonates.301 302 303 306 314 324 325 326 329 348 371 Monitor renal function and serum electrolytes.301

Hyperkalemia reported in adults.341 420

Hematologic Effects

Potential for spontaneous intraventricular hemorrhage in neonates.301 Observe premature infants for signs of bleeding.301

Contraindicated in neonates who are bleeding and in those with thrombocytopenia or coagulation defects.301

Ocular Effects

Corneal deposits and retinal disturbances reported in patients receiving long-term therapy.341 420 Ophthalmic examination recommended in patients with blurred vision; periodic ophthalmic examinations recommended in patients receiving long-term therapy.341 420

CNS Effects

May aggravate depression or other psychiatric disturbances, epilepsy, or parkinsonism; use with caution in patients with these conditions.341 420

May cause drowsiness; may impair ability to perform activities requiring mental alertness.341 420

May cause headache.341 420 Discontinue the drug in patients in whom indomethacin-induced headache persists despite a reduction in dosage.341 420

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylactoid reactions (e.g., anaphylaxis, angioedema) reported.341 420

Immediate medical intervention and discontinuance for anaphylaxis.341 420

Avoid in patients with aspirin triad (aspirin sensitivity, asthma, nasal polyps); caution in patients with asthma.341 420

Dermatologic Reactions

Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.420 Discontinue at first appearance of rash or any other sign of hypersensitivity (e.g., blisters, fever, pruritus).420

General Precautions

Hepatic Effects

Severe reactions including jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure (sometimes fatal) reported rarely with NSAIAs.341 420

Elevations of serum ALT or AST reported.341 420

Monitor for symptoms and/or signs suggesting liver dysfunction; monitor abnormal liver function test results.341 420 Discontinue if signs or symptoms of liver disease or systemic manifestations (e.g., eosinophilia, rash) occur or if liver function test abnormalities persist or worsen.301 341 420

Hematologic Precautions

Anemia reported rarely.420 Determine hemoglobin concentration or hematocrit in patients receiving long-term therapy if signs or symptoms of anemia occur.420

May inhibit platelet aggregation and prolong bleeding time.341 420 When used for inflammatory diseases, use with caution in patients with coagulation defects.341 420

Other Precautions

Not a substitute for corticosteroid therapy; not effective in the management of adrenal insufficiency.420

May mask certain signs of infection.340 341 420

Obtain CBC and chemistry profile periodically during long-term use.420

Specific Populations


Category C.420 Avoid use in third trimester because of possible premature closure of the ductus arteriosus.341 420


Distributed into milk; use not recommended.341 420

Pediatric Use

Safety and efficacy established in neonates receiving the drug for PDA.301

Safety and efficacy of oral or rectal indomethacin not established in children ≤14 years of age.341 420

Indomethacin should not be used in children 2–14 years of age unless toxicity or lack of efficacy with other drugs justifies the risk.420

Adverse effects reported in children receiving indomethacin capsules generally comparable to those reported in adults.420 Hepatotoxicity, sometimes fatal, has been reported in pediatric patients with juvenile rheumatoid arthritis.420 Periodic assessment of liver function recommended.420

Geriatric Use

Caution advised.420 Geriatric patients appear to tolerate NSAIA-induced adverse effects less well than younger individuals.341 420 Fatal adverse GI effects reported more frequently in geriatric patients than younger adults.341 420

Possible confusion or, rarely, psychosis in geriatric patients.420

Substantially eliminated by the kidney; select dosage carefully and assess renal function periodically since geriatric patients more likely to have decreased renal function.341 420

Renal Impairment

Use not recommended in patients with advanced renal disease; close monitoring of renal function advised if used.420

Common Adverse Effects

With oral therapy, nausea, dyspepsia, headache, dizziness.341 420

With rectal administration, rectal irritation, tenesmus; adverse effects associated with oral administration possible.420

With IV therapy, bleeding,301 302 303 305 306 310 315 316 322 323 346 347 348 349 350 351 352 353 354 transient oliguria,301 302 303 306 309 314 315 324 325 326 329 346 347 348 350 353 354 355 357 358 359 371 increases in serum creatinine concentrations,301 302 303 306 314 324 325 326 329 348 371 hyponatremia,301 elevated serum potassium concentrations.301

Interactions for Indocin

Protein-bound Drugs

Possible pharmacokinetic interaction; observe for adverse effects if used with other protein-bound drugs.a

Drugs Excreted by the Kidney

Possible pharmacokinetic interaction with drugs that rely on adequate renal function for excretion.301 In neonates receiving IV indomethacin, consider dosage adjustment for drugs that rely on adequate renal function for excretion.301

Specific Drugs




ACE inhibitors

Reduced BP response to ACE inhibitor341 420 440 441 442 443 444 445 446 447

Possible deterioration of renal function in individuals with renal impairment420

Monitor BP341 420

Aminoglycosides (amikacin, gentamicin)

Increased plasma aminoglycoside concentrations reported in neonates receiving IV indomethacin301 372

Monitor serum aminoglycoside concentrations and renal function372

Angiotensin II receptor antagonists

Reduced BP response to angiotensin II receptor antagonist420

Possible deterioration of renal function in individuals with renal impairment420

Monitor BP420

Antacids (aluminum- or magnesium-containing)

Slight reduction or delay in peak plasma indomethacin concentrationa

Clinical importance not establisheda


Possible bleeding complications; pharmacodynamic interaction not observed in clinical studies 420

Monitor anticoagulant activity;341 420 caution advised420


Bleeding time prolongeda

β-adrenergic blocking agents

Reduced BP response to β-adrenergic blocking agent341 420

Monitor BP 420


Possible increase in cyclosporine toxicity341 420

Use with caution; monitor renal function341 420


Increased serum concentration and half-life of digoxin301 341 369 370 420

Monitor serum digoxin concentrations301 341 420

Consider digoxin dosage reduction in neonates; 369 370 monitor ECG301 369 370

Diuretics (furosemide, thiazides)

Reduced natriuretic effects301 341 420

Pharmacokinetic interaction with hydrochlorothiazide unlikely367 368

Monitor for diuretic efficacy and renal failure420

Concomitant administration of furosemide used to therapeutic advantage in neonates301 324

Diuretics (potassium-sparing)

Increased serum potassium concentrations341 420

Acute renal failure reported in adults receiving triamterene341 366 420

Should not be administered concomitantly with triamterene341 420


Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya


Reduced BP response to hydralazine393

Monitor BP393


Increased plasma lithium concentrations341 420

Monitor for lithium toxicity341 420


Possible increased plasma methotrexate concentrations420

Caution advised341 420


NSAIAs including aspirin: Potential for increased risk of GI toxicity with little or no increase in efficacy341 420

Aspirin: No consistent evidence that low-dose aspirin mitigates the increased risk of serious cardiovascular events associated with NSAIAs420 502 508

Aspirin: Decreased plasma indomethacin concentrations reported with concomitant aspirin (3.6 g daily) therapy341 420

Diflunisal: Increased plasma indomethacin concentrations and serious GI adverse effects reported341 420

Concomitant use not recommended341 420

Potassium supplements

Increased serum potassium concentrations362

Caution advised362


Increased plasma concentrations of free prednisolone; total plasma prednisolone concentrations unchangeda


Increased plasma concentrations of indomethacin341 420

Select and adjust indomethacin dosage with care; lower dosage may be adequate341 420


Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya


Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya

Thrombolytic agents

Possible bleeding complicationsa

Caution adviseda

Indocin Pharmacokinetics



Well absorbed from the GI tract.341 420 Almost completely absorbed following oral administration as conventional or extended-release capsules;341 420 bioavailability following rectal administration is 80–90% of that of the conventional capsule.420

Indomethacin extended-release capsules release 25 mg of drug initially and the remaining 50 mg over 12 hours.341

When administered with food, the commercially available conventional capsules and oral suspension are bioequivalent.420



Crosses the placenta and blood-brain barrier.301

Concentrations in synovial fluid 20% of those in serum.a

Distributed into milk.341 420

Plasma Protein Binding

99% (in adults).341 420



Metabolized in the liver.341 420

Elimination Route

Undergoes appreciable enterohepatic circulation.301 341 420 Following oral administration, excreted in the urine (60%) and feces (33%) as unchanged drug and metabolites.341 420


Adults: 4.5 hours.341 420

Neonates <7 days of age: 20 hours.301

Neonates >7 days of age: 12 hours.301

Neonates weighing <1 kg: 21 hours.301

Neonates weighing >1 kg: 15 hours.301




Conventional or Extended-release Capsules

15–30°C.a 341


<30°C; avoid temperatures >50°C.420 Protect from freezing.420



<30°C; avoid temperatures >40°C (even transiently).420


Powder for Injection

<30°C; protect from light.301


For information on systemic interactions resulting from concomitant use, see Interactions.


Solution Compatibility

Reconstitute with preservative-free sterile water for injection or preservative-free 0.9% sodium chloride injection.301 Further dilution with IV solutions is not recommended.301

Drug Compatibility
Syringe CompatibilityHID


Pantoprazole sodium

Y-Site CompatibilityHID



Potassium chloride

Sodium bicarbonate

Sodium nitroprusside


Amino acid injection (TrophAmine)

Calcium gluconate

Cimetidine HCl

Dobutamine HCl

Dopamine HCl

Gentamicin sulfate


Tobramycin sulfate


Dextrose injection


  • Inhibits cyclooxygenase-1 (COX-1) and COX-2.301 341 420 455 456 457 458 461 462 463

  • Pharmacologic actions similar to those of other prototypical NSAIAs; exhibits anti-inflammatory, analgesic, and antipyretic activity.301 341 420

  • Permits closure of the ductus arteriosus in premature neonates by inhibiting prostaglandin synthesis.301

Advice to Patients

  • Importance of reading the medication guide for NSAIAs that is provided each time the drug is dispensed.420

  • Risk of serious cardiovascular events (e.g., MI, stroke).420 500 508

  • Risk of GI bleeding and ulceration.341 420

  • Risk of serious skin reactions.420 Risk of anaphylactoid and other sensitivity reactions.420

  • Risk of hepatotoxicity.341 420

  • Risk of ocular toxicity.341 420

  • Potential for drug to impair mental alertness; use caution when driving or operating machinery until effects on individual are known.341 420

  • Importance of seeking immediate medical attention if signs and symptoms of a cardiovascular event (chest pain, dyspnea, weakness, slurred speech) occur.420 500 508

  • Importance of notifying clinician if signs and symptoms of GI ulceration or bleeding, unexplained weight gain, or edema develops.341 420

  • Importance of discontinuing indomethacin and contacting clinician if rash or other signs of hypersensitivity (blisters, fever, pruritus) develop.420 Importance of seeking immediate medical attention if an anaphylactic reaction occurs.341 420

  • Importance of discontinuing therapy and contacting clinician immediately if signs and symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, upper right quadrant tenderness, flu-like symptoms) occur.341 420

  • Risk of heart failure or edema; importance of reporting dyspnea, unexplained weight gain, or edema.508

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.341 420 Importance of avoiding indomethacin in late pregnancy (third trimester).341 420

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.341 420

  • Importance of informing patients of other important precautionary information.341 420 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names




25 mg*

Indomethacin Capsules

50 mg*

Indomethacin Capsules

Capsules, extended-release

75 mg*

Indomethacin Extended-release Capsules


25 mg/5 mL





50 mg*



Indomethacin Suppositories

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Indomethacin Sodium


Dosage Forms


Brand Names



For injection, for IV use only

1 mg (of anhydrous indomethacin)*

Indomethacin Sodium for Injection

AHFS DI Essentials™. © Copyright 2020, Selected Revisions November 21, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


236. Mathe AA. False normal dexamethasone suppression test and indomethacin. Lancet. 1982; 2:714.

300. Paulus HE. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1985; 28:1168-9.

301. Ovation Pharmaceuticals. Indocin I.V. (indomethacin sodium trihydrate) prescribing information. Deerfield, IL; 2005 Sep.

302. Yeh TF, Luken JA, Thalji A et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus—a double-blind controlled study. J Pediatr. 1981; 98:137-45.

303. Harris JP, Merritt TA, Alexson CG et al. Parenteral indomethacin for closure of the patent ductus arteriosus: clinical experience with 67 preterm infants. Am J Dis Child. 1982; 136:1005-8.

304. Smith IJ, Goss I, Congdon PJ. Intravenous indomethacin for patent ductus arteriosus. Arch Dis Child. 1984; 59:537-41.

305. Merritt TA, Harris JP, Roghmann K et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. J Pediatr. 1981; 99:281-6.

306. Gersony WM, Peckham GJ, Ellison RC et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983; 102:895-906.

307. Ellison RC, Peckham GJ, Lang P et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics. 1983; 71:364-72.

308. Brash AR, Hickey DE, Graham TP et al. Pharmacokinetics of indomethacin in the neonate: relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med. 1981; 305:67-72.

309. Mellander M, Leheup B, Lindstrom DP et al. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr. 1984; 105:138-43.

310. Yeh TF, Goldbarg HR, Henek T et al. Intravenous indomethacin therapy in premature infants with patent ductus arteriosus: causes of death and one-year follow-up. Am J Dis Child. 1982; 136:803-7.

311. Jacob J, Gluck L, DiSessa T et al. The contribution of PDA in the neonate with severe RDS. J Pediatr. 1980; 96:79-87.

312. Halliday HL. Indomethacin for persistent ductus arteriosus. Lancet. 1980; 2:314.

313. Anon. I.V. indomethacin approved to close patent ductus arteriosus. FDA Drug Bull. 1985; 15:4-5.

314. Thalji AA, Car I, Yeh TF et al. Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr. 1980; 97:995-1000.

315. Mahony L, Carnero V, Brett C et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med. 1982; 306:506-10.

316. Mahony L, Caldwell RL, Girod DA et al. Indomethacin therapy on the first day of life in infants with very low birth weight. J Pediatr. 1985; 106:801-5.

317. Seyberth HW, Knapp G, Wolf D et al. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr. 1983; 141:71-6.

318. Smallhorn JF, Gow R, Olley PM et al. Combined noninvasive assessment of the patent ductus arteriosus in the preterm infant before and after indomethacin treatment. Am J Cardiol. 1984; 54:1300-4.

319. Peckham GJ, Miettinen OS, Ellison RC et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. J Pediatr. 1984; 105:285-91.

320. Maher P, Lane B, Ballard R et al. Does indomethacin cause extension of intracranial hemorrhages: a preliminary study. Pediatrics. 1985; 75:497-500.

321. Page GG. Patent ductus arteriosus in the premature neonate. Heart Lung. 1985; 14:156-62.

322. Merritt TA, White CL, Coen RW et al. Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy. Am J Dis Child. 1982; 136:507-12.

323. Corazza MS, Davis RF, Merritt TA et al. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr. 1984; 105:292-6.

324. Yeh TF, Wilks A, Singh J et al. Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J Pediatr. 1982; 101:433-7.

325. Betkerur MV, Yeh TF, Miller K et al. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981; 68:99-102.

326. Seyberth HW, Rascher W, Hackenthal R et al. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. J Pediatr. 1983; 103:979-84.

327. Law WM Jr, Heath H III. Familial benign hypercalcemia (hypocalciuric hypercalcemia): clinical and pathogenetic studies in 21 families. Ann Intern Med. 1985; 102:511-9.

328. Dzau VJ, Packer M, Lilly LS et al. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984; 310:347-52.

329. Catterton Z, Sellers B, Gray B. Inulin clearance in the premature infant receiving indomethacin. J Pediatr. 1980; 96:737-9.

330. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents: effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol. 1984; 102:1453-6.

331. Kraff MC, Sanders DR, Jampol LM et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982; 89:885-90.

332. Kraff MC, Sanders DR, Peyman GA et al. Slit-lamp fluorophotometry in intraocular lens patients. Ophthalmology. 1980; 87:877-80.

333. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol. 1980; 64:324-8.

334. Yannuzzi LA, Landau AN, Turtz AI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology. 1981; 88:947-54.

335. Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol. 1984; 28(Suppl):554-68.

336. Yamaaki H, Hendrikse F, Deutman F. Iris angiography after cataract extraction and the effect of indomethacin eyedrops. Ophthalmologica. 1984; 188:82-6.

337. Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema: 1985 update. Ophthalmology. 1985; 92:807-10.

338. Kraff MC, Sanders DR, Jampol LM et al. Factors affecting pseudophakic cystoid macular edema: five randomized trials. J Am Intraocul Implant Soc. 1985; 11:380-5.

339. Miyake K, Miyake Y, Maekubo K et al. Incidence of cystoid macular edema after retinal detachment surgery and the use of topical indomethacin. Am J Ophthalmol. 1983; 95:451-6.

340. Sanders DR, Goldstick B, Kraff C et al. Aqueous penetration of oral and topical indomethacin in humans. Arch Ophthalmol. 1983; 101:1614-6.

341. Eon Labs. Indomethacin extended-release capsules prescribing information. Laurelton, NY; 2000 Apr.

342. Ment LR, Duncan CC, Ehrenkranz RA et al. Randomized indomethacin trial for the prevention of intraventricular hemorrhage in very low birth weight infants. J Pediatr. 1985; 107:937-43.

343. Setzer ES, Webb IB, Wassenaar JW et al. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr. 100:599-605.

344. Lanza FL, Umbenhauer ER, Nelson RS et al. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumatol. 1982; 9:415-9.

345. Hansen TM, Matzen P, Madsen P. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol. 1984; 11:484-7.

346. Friedman Z, Whitman V, Maisels MJ et al. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol. 1978; 18:272-9.

347. Harinck E, van Ertbruggen I, Senders RC et al. Problems with indomethacin for ductus closure. Lancet. 1977; 2:245.

348. Petersen S, Christensen NC et al. Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus. Acta Paediatr Scand. 1981; 70:729-33.

349. Kennedy JD, Jones RCM, Hudson SA et al. Patent ductus arteriosus in premature babies. BMJ. 1982; 284:114-5.

350. Yanagi RM, Wilson A, Newfeld EA et al. Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics. 1981; 67:647-52.

351. Alpan G, Eyal F, Vinograd I et al. Localized intestinal perforations after enteral adminstration of indomethacin in premature infants. J Pediatr. 1985; 106:277-81.

352. Campbell AN, Beasley JR, Kenna AP. Indomethacin and gastric perforation in a neonate. Lancet. 1981; 1:1110-1.

353. Nagaraj HS, Sandhu AS, Cook LN et al. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg. 1981; 16:1003-7.

354. Neal WA, Kyle JM, Mullett MD. Failure of indomethacin therapy to induce closure of patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr. 1977; 91:621-3.

355. Merritt TA, DiSessa TG, Feldman BH et al. Closure of patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr. 1978; 93:639-46.

356. Merritt TA, White CL, Jacob J et al. Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study. J Pediatr. 1979; 95:588-94.

357. Friedman WF, Hirschklau MJ, Printz MP et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976; 295:526-9.

358. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics. 1978; 62:706-12.

359. Heyman MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976; 295:530-3.

360. Procianoy RS, Garcia-Prats JA, Hittner HM et al. Use of indomethacin and its relationship to retinopathy of prematurity in very low birthweight infants. Arch Dis Child. 1980; 55:362-4.

361. Yeh TF, Raval D, Pyati S et al. Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins. 1983; 25:385-91.

362. Zimran A, Kramer M, Plaskin M et al. Incidence of hyperkalaemia induced by indomethacin in a hospital population. BMJ. 1985; 291:107-8.

363. Rasmussen LF, Ahlfors CE, Wennberg RP. Displacement of bilirubin from albumin by indomethacin. J Clin Pharmacol. 1978; 18:477-81.

364. Yeh TF, Raval D, Lilien LD et al. Decreased plasma glucose after indomethacin therapy in premature infants with patent ductus arteriosus. Lancet. 1982; 2:104-5.

365. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med. 1982; 96:317-20.

366. Weinberg MS, Quigg RJ, Salant DJ et al. Anuric renal failure precipitated by indomethacin and triamterene. Nephron. 1985; 40:216-8.

367. Williams RL, Davies RO, Berman RS et al. Hydrochlorothiazide pharmacokinetics and pharmacologic effect: the influence of indomethacin. J Clin Pharmacol. 1982; 22:32-41.

368. Koopmans PP, Kateman WGPM, Tan Y et al. Effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clin Pharmacol Ther. 1985; 37:625-8.

369. Koren G, Zarfin Y, Perlman M et al. Effects of indomethacin on digoxin pharmacokinetics in preterm infants. Pediatr Pharmacol. 1984; 4:25-30.

370. Zarfin Y, Koren G, Perlman M. Digoxin and indomethacin in preterm infants with PDA. J Pediatr. 1984; 105:678-9.

371. John EG, Vasan U, Hastreiter AR et al. Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus. Pediatr Pharmacol. 1984; 4:11-9.

372. Zarfin Y, Koren G, Maresky D et al. Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr. 1985; 106:511-3.

373. Bennett WM, Aronoff GR, Golper TA et al. Drug prescribing in renal failure: dosing guidelines for adults. Philadelphia: American College of Physicians; 1987:74-5.

374. AMA Department of Drugs. AMA drug evaluations. 5th ed. Chicago: American Medical Association;

375. Settipane GA. Adverse reactions to aspirin and other drugs. Arch Intern Med. 1981; 141:328-32.

376. Weinberger M. Analgesic sensitivity in children with asthma. Pediatrics. 1978; 62(Suppl):910-5.

377. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983; 74(Suppl):102-9.

378. VanArsdel PP Jr. Aspirin idiosyncracy and tolerance. J Allergy Clin Immunol. 1984; 73:431-3.

379. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984; 74(4 Part 2):617-22.

380. Stevenson DD, Mathison DA. Aspirin sensitivity in asthmatics: when may this drug be safe? Postgrad Med. 1985; 78:111-3,116-9. (IDIS 205854)

381. The Upjohn Company. Motrin prescribing information. Kalamazoo, MI; 1985 Jul.

382. McNeil Pharmaceutical. Tolectin DS and Tolectin prescribing information. Spring House, PA; 1985 Aug.

383. Syntex Puerto Rico, Inc. Naprosyn prescribing information. Humacao, PR; 1985 Jun.

384. Pleskow WW, Stevenson DD, Mathison DA et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982; 69(1 Part 1):11-9.

385. Thyss A, Milano G, Kubar J et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986; 1:256-8.

386. Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep. 1985; 69:342-3.

387. Singh RR, Malaviya AN, Pandey JN et al. Fatal interaction between methotrexate and naproxen. Lancet. 1986; 1:1390.

388. Day RO, Graham GG, Champion GD et al. Anti-rheumatic drug interactions. Clin Rheum Dis. 1984; 10:251-75.

389. Daly HM, Scott GL, Boyle J et al. Methotrexate toxicity precipitated by azapropazone. Br J Dermatol. 1986; 114:733-5.

390. Hansten PD, Horn JR. Methotrexate interactions: ketoprofen (Orudis). Drug Interact Newsl. 1986; 6(Updates):U5-6.

391. Hansten PD, Horn JR. Methotrexate and nonsteroidal anti-inflammatory drugs. Drug Interact Newsl. 1986; 6:41-3.

392. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986; 1:1390.

393. Cinquegrani MP, Liang CS. Indomethacin attenuates the hypotensive action of hydralazine. Clin Pharmacol Ther. 1986; 39:564-70.

394. Ment LR. Indomethacin for prevention of intraventricular hemorrhage. J Pediatr. 1986; 109:397-8.

395. Barrington KJ. Indomethacin for prevention of intraventricular hemorrhage. J Pediatr. 1986; 109:396-7.

396. Cowan F. Indomethacin, patent ductus arteriosus, and cerebral blood flow. J Pediatr. 1986; 109:341-4.

397. Gordon RD, Tunny TJ, Klemm SA et al. Indomethacin and atrial natriuretic peptide in Bartter’s syndrome. N Engl J Med. 1986; 315:459.

398. Vanhaesebrouck P, Thiery M, Leroy JG et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr. 1988; 113:738-43.

399. Moise KJ, Huhta JC, Sharif DS et al. Indomethacin in the treatment of premature labor: effects on the fetal ductus arteriosus. N Engl J Med. 1988; 319:327-31.

400. Krueger E, Mellander M, Bratton D et al. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr. 1987; 111:749-54.

401. Clyman RI, Campbell D. Indomethacin therapy for patent ductus arteriosus: when is prophylaxis not prophylactic? J Pediatr. 1987; 111:718-22. Editorial.

402. Setzer Bandstra E, Montalvo BM, Goldberg RN et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics. 1988; 82:533-42.

403. Ment LR, Duncan CC, Ehrenkranz RA et al. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr. 1988; 112:948-55.

404. Ramsay JM, Murphy DJ, Vick W III et al. Response of patent ductus arteriosus to indomethacin treatment. Am J Dis Child. 1987; 141:294-7.

405. Hanigan WC, Kennedy G, Roemisch F et al. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates. J Pediatr. 1988; 112:941-7.

406. Palmer JF. Letter sent to Berger ET, of Merck Sharp & Dohme regarding labeling revisions about gastrointestinal adverse reactions to Indocin (indomethacin). Rockville, MD: Food and Drug Administration, Division of Oncology and Radiopharmaceutical Drug Products; 1988 Sep.

407. Food and Drug Administration. Labeling revisions for NSAIDs. FDA Drug Bull. 1989; 19:3-4.

408. Searle. Cytotec (misoprostol) prescribing information. Skokie, IL; 1989 Jan.

409. Anon. Drugs for rheumatoid arthritis. Med Lett Drugs Ther. 2000; 42:57-64.

410. Soll AH, Weinstein WM, Kurata J et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991; 114:307-19.

411. Digoxin/indomethacin. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1991:285.

412. Jorgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol. 1991; 31:108-10.

413. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991; 115:165-72.

414. Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease—still unsettled. Ann Intern Med. 1991; 115:227-8.

415. Stillman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity: should we be concerned? Arch Intern Med. 1990; 150:268-70.

416. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med. 1990; 112:559-60.

417. Finch MB, Johnston GD, McDevitt DG. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol. 1984; 17:353-5.

418. Murray MD, Brater DC, Tierney WM et al. Ibuprofen-associated renal impairment in a large general medicine practice. Am J Med Sci. 1990; 299:222-9.

419. Reviewers’ comments (personal observations).

420. Merck. Indocin (indomethacin) capsules, oral suspension, and suppositories prescribing information. Whitehouse Station, NJ; 2007 Mar.

421. Merck, West Point, PA: Personal communication.

422. Coombs RC, Morgan MEI, Durbin GM et al. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child. 1990; 65:1067-71.

423. Rajadurai VS, Yu VYH. Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. J Paediatr Child Health. 1991; 27:370-5.

424. Edwards AD, Wyatt JS, Richardson C et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990; 335:1491-5.

425. Colditz P, Murphy D, Rolfe P et al. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm infants. Arch Dis Child. 1989; 64:8-12.

426. Pryds O, Greisen G, Johansen KH. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr. 1988; 147:315-6.

427. Evans DH, Levene MI, Archer LNJ. The effect of indomethacin on cerebral blood-flow velocity in premature infants. Dev Med Child Neurol. 1987; 29:776-82.

428. Mardoum R, Bejar R, Merritt TA et al. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. J Pediatr. 1991; 118:112-5.

429. Hammerman C, Glaser J, Schimmel MS et al. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics. 1995; 95:244-8.

430. Austin NC, Pairaudeau PW, Hames TK et al. Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. Arch Dis Child. 1992; 67:851-4.

431. Simko A, Mardoum R, Merritt TA et al. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol. 1994; 14:29-35.

432. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994; 96:274-81.

433. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bledding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343:769-72.

434. Schubert TT, Bologna SD, Yawer N et al. Under risk factors: interaction between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med. 1993; 94:413-7.

435. Bateman DN, kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients: the medicine may be worse that than the disease. BMJ. 1995; 310:817-8.

436. Corticosteroid interactions: nonsteroidal anti-inflammatory drugs (NSAIDs). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:562.

437. Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Am Intern Med. 1991; 114:735-40.

438. Geigy, Ardsley, NY: Personal communication on diclofenac 28:08.04.

439. Reviewers’ comments (personal observation) on diclofenac 28:08.04.

440. McNeil. Motrin (ibuprofen suspension, chewale tablets, caplets) prescribing information. Fort Washington, PA; 1994 Dec.

441. Abe K, Ito T, Sato M et al. Role of prostaglandin in the antihypertensive mechanism of captopril in low renin hypertension. Clin Sci. 1980; 59:141-4s.

442. Antiotensin-converting enzyme inhibitor interactions: nonsteroidal anti-inflammatory drugs (NSAIDs). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:131-2.

443. ACE inhibitors/indomethacin. In: Tatro DS, olin BR, Hebel SK et al. Drug interaction facts. St. Louis: JB Lippincott Co; 1992(April):28.

444. Salvetti A, Abdel-Haq B, Magagna A et al. Indomethacin reduces the antihypertensive action of enalapril. Clin Exp Hypertens. 1987; 9:559-67.

445. Fujita T. Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients. Clin Exp Hypertens. 1981; 3:939-52.

446. Moore TJ, Crantz FR, Hollenberg NK et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension. 1981; 3:168-73.

447. Silberbauer K, Stanek B, Templ H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol. 1982; 14(Suppl 2):87-93S.

448. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J. 1990; 83:1144-8.

449. Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996; 46:1470.

450. Schatz IJ. Farewell to the “Shy-Drager syndrome”. Ann Intern Med. 1996; 125:74-5.

451. Sidmak Laboratories. Indomethacin capsules, USP, prescribing information. East Hanover, NJ; 1996 June.

452. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). From website.

453. Friedman PL, Brown EJ Jr, Gunther S et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med. 1981; 305:1171-5.

454. Hammerman H, Schoen FJ, Braunwald E et al. Drug-induced expansion of infarct: morphologic and functional correlations. Circulation. 1984; 69:611-7.

455. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase—a review. Prostaglandins Other Lipid Mediators. 1998; 56:341-61.

456. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999; 106(Suppl 5B):37-42S.

457. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888-99.

458. Hawkey CJ. COX-2 inhibitors. Lancet. 1999; 353:307-14.

459. Morrison BW, Daniels SE, Kotey P et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled study. Obstet Gynecol. 1999;94:504-8.

461. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384:644-8.

462. Riendeau D, Charleson S, Cromlish W et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997; 75:1088-95.

463. DeWitt DL, Bhattacharyya D, Lecomte M et al. The differential susceptibility of prostaglandin endoperoxide H synthases-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res. 1995; 5:325-43.

464. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328-46.

465. Vermillion ST, Newman RB. Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am J Obstet Gynecol. 1999; 181:1083-6.

466. Abramov Y, Nadjari M, Weinstein D et al. Indomethacin for preterm labor: a randomized comparison of vaginal and rectal-oral routes. Obstet Gynecol. 2000; 95:482-6.

467. Katz VL, Farmer RM. Controversies in tocolytic therapy. Clin Obstet Gynecol. 1999; 42:802-19.

468. Higby K, Suiter CR. A risk-benefit assessment of therapies for premature labour. Drug Saf. 1999; 21:35-56.

469. Macones GA, Robinson CA. Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol. 1997; 177:819-24.

470. Panter KR, Hannah ME, Amankwah KS et al. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynecol. 1999; 106:467-73.

471. Lanza FL, and the members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998; 93:2037-46.

472. Schmidt B, Davis P, Moddemann D et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001; 344:1966-72.

473. Hammerman C, Kaplan M. Comparative tolerability of pharmacological treatments for patent ductus arteriosus. Drug Safety. 2001; 24:537-51.

474. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999; 26(suppl 56):18-24.

475. in’t Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001; 345:1515-21.

476. Breitner JCS, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer’s disease? N Engl J Med. 2001; 345:1567-8. Editorial.

477. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996; 47:425-32.

478. Beard CM, Waring SC, O’sBrien PC et al. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc. 1998; 73:951-5.

479. in’t Veld BA, Launer LJ, Hoes AW et al. NSAIDs and incident Alzheimer’s disease: the Rotterdam Study. Neurobiol Aging. 1998; 19:607-11.

480. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997; 48:626-32.

481. Pharmacia. Daypro (oxaprozin) caplets prescribing information. Chicago, IL; 2002 May.

482. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347:2104-10.

483. Graham DY. NSAIDs, Helicobacter pylori, and Pandora’s box. N Engl J Med. 2002; 347:2162-4.

484. Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 2005 Apr 6.

485. Cush JJ. The safety of COX-2 inhibitors: deliberations from the February 16-18, 2005, FDA meeting. From the American College of Rheumatology website ( Accessed 2005 Oct 12.

486. Novartis Pharmaceuticals. Diovan (valsartan) capsules prescribing information (dated 1997 Apr). In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:2013-5.

487. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296; 1633-44.

488. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332; 1302-5.

489. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk; the seduction of common sense. JAMA. 2006; 296:1653-6.

490. Chou R, Helfand M, Peterson K et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4. (Prepared by the Oregon evidence-based practice center under contract no. 290-02-0024.) . Rockville, MD: Agency for Healthcare Research and Quality. 2006 Sep. Available at:

491. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O'Gara PT et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61:e78-140.

500. Food and Drug Administration. Drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Silver Spring, MD; 2015 Jul 9. From the FDA web site. Accessed 2016 Mar 22.

501. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382:769-79.

502. Food and Drug Administration. FDA briefing document: Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee, February 10-11, 2014. From FDA web site

503. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342:c7086.

504. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009; 169:141-9.

505. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123:2226-35.

506. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8:e1001098.

507. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62:e147-239.

508. Mylan. Indomethacin capsules prescribing information. Morgantown, WV; 2016 May.

511. Olsen AM, Fosbøl EL, Lindhardsen J et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012; 126:1955-63.

512. Olsen AM, Fosbøl EL, Lindhardsen J et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study. PLoS One. 2013; 8:e54309.

516. Bavry AA, Khaliq A, Gong Y et al. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med. 2011; 124:614-20.

a. AHFS drug information 2003. McEvoy GK, ed. Indomethacin/Indomethacin Sodium. Bethesda, MD: American Society of Health-System Pharmacists; 2003;1954-64.

b. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:705-14.

HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:940-1.

Related questions